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Background: Slimming products represent a dynamically growing group of food
supplements worldwide. The efficacy of safely usable natural ingredients is usually
below consumers’ expectations. Certain manufacturers add unauthorized or prohibited
ingredients to weight loss supplements in order to increase their efficacy. Hence, many of
these products are adulterated and may pose a risk to the consumers’ health.
Aims: The aim of our work was to give an overview on natural ingredients used in slimming
products, to summarize the frequently used synthetic adulterants and also to assess the
trends of adulterated and illegal food supplements in the European Union based on the
warnings of the Rapid Alert System for Food and Feed (RASFF) in the time period of
1988–2019.
Methods: Reports between 1988–2019 were extracted from the RASFF portal on
January 1, 2020. Each entry was individually reviewed.
Results: 2,559 records of food supplements with quality problems were identified in the
RASFF, several of which [319 (12,5%)] were marketed to facilitate weight loss. 202 (63,3%)
contained unapproved, synthetic drug ingredients. The major adulterant (113 of 319,
35.4%) was DNP (2,4-dinitrophenol), whereas sibutramine was the second most frequent
adulterant agent (69 products, 21,6%) between 1988 and 2019.
Conclusion: The number of approved medicines for the indication of weight loss is
relatively low and their efficacy (and also that of the natural ingredients) is limited. Therefore,
a significant number of weight loss supplements is adulterated to satisfy patients’
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INTRODUCTION
Obesity is an emerging health problem worldwide, the number of
affected people doubled from 1980 to 2008 (Finucane et al., 2011).
Not only the incidence of obesity has been growing, but the
world’s population’s mean BMI has also been increasing by a
significant 0.4–0.5 kg/m2 in each decade (Finucane et al., 2011).
Based on the World Health Organization’s (WHO) estimates,
almost two billion adults had a body-mass index (BMI) ≥ 25.0
and of these adults more than 650 million people were classified
as obese (BMI ≥30.0) in 2016 (World Health Organisation, 2018;
Montan et al., 2019). Obesity does not only affect the
United States, but it is becoming an epidemic also in Europe
and even in several developing countries (Barness et al., 2007).
According to a recently issued report, approximately 23% of the
female and 20% of the male population of Europe were
considered obese (World Health Organisation, 2019). If game-
changing measures are not going to be applied, by the end of this
decade, more than half of the world’s adult population will be
obese or at least overweight (Kelly et al., 2008). Obesity is
associated with many comorbidities, including cardiovascular
(e.g. heart disease, hypertension) and cerebrovascular (e.g.
stroke) ailments. The incidence of other severe chronic
diseases, such as type 2 diabetes mellitus (T2DM) and
degenerative musculoskeletal diseases (e.g. arthritis) are higher
among overweight and obese people than among people with
normal BMI. Moreover, Alzheimer’s disease and some malignant
tumors affect more often obese people (World Health
Organisation, 2018). Lifestyle interventions, involving dietary
modifications and increased physical activity are of high
importance in avoiding obesity; however, a high proportion of
the individuals loses interest shortly after they have started their
new lifestyle and return to their original one; therefore, the results
are rarely permanent (Curioni and Lourenço, 2005). In the past
century, many pharmacons have been approved to support
weight loss; however, currently only three APIs and one
combination product are available for this indication in the
European Union (EU) (Tonstad et al., 2016). Several
medicines are no longer available on the market because of
safety concerns. Alternative methods are sought-after in the
treatment of obesity. The most commonly used products for
this purpose are food supplements, which are easily available on
the market. However, these products are often counterfeited,
containing illegal components. RASFF was set up to aid the
national competent authorities in harmonizing their actions
and informing one another in the control of food and feed
that are posing serious risks (Rapid Alert System for Food and
Feed (RASFF), 2020). RASFF is used in the European Union to
help obtain the minimally required safety and quality of feed and
food (i.e. safety and quality).
The goals of our study were to give an overview on the most
widely used natural products, and on the safety profiles of
available and withdrawn pharmacons that might be used to
facilitate weight loss. We also aimed to assess their presence in
food supplements on the European market associated with a
warning released by RASFF and to summarize the trends from
1988 to 2019.
PHARMACOTHERAPY OF OBESITY
According to current guidelines, complex measures should be
considered in obese patients and pharmacological therapy should
only be used along other lifestyle modifications. Actions to
address weight management should not only be applied in
obese people (BMI ≥30), but also in patients with a BMI
≥27 kg/m2 if they already have metabolic syndrome or sleep
apnea. The efficacy of pharmacotherapy should be assessed
and reconsidered within 3 months of initiating the treatment
(Yumuk et al., 2015), and it is highly recommended to complete
pharmacotherapy with comprehensive lifestyle modifications
including calorie deficit and pronounced physical activity.
A great deal of pharmacons previously used in weight
management are no longer marketed because of safety issues.
These drugs involve amphetamine derivatives, fenfluramine,
lorcaserin, phenylpropanolamine, rimonabant, and sibutramine
(Bray, 2014; Morris, 2018). The emerged safety concerns
highlight that the potential side-effects (CNS-depressing
effects, insomnia, toxicity, primary pulmonary hypertension)
of pharmacons inducing weight loss should be monitored and
assessed more thoroughly (Montan et al., 2019). Currently
available medications for this purpose in the European Union
are orlistat, liraglutide, naltrexone/bupropion and phentermine
resinate (Yumuk et al., 2015; EMA 2020b; The State Institute for
Drug Control (SUKL), 2020).
In the meantime, the popularity of food supplements for
weight loss management and their market share have been
increasing (Ríos-Hoyo and Gutiérrez-Salmeán, 2016).
Unfortunately, some products are adulterated with synthetic
substances, usually formerly approved weight loss compounds,
which had already been withdrawn from the market. Hence, these
food supplements can pose serious health risks for consumers.
Medications of Obesity Available in the
European Union
Orlistat
Orlistat (1) gained its marketing approval for obesity
management by the European Commission (EC) in 1998
(Supplementary Table S1). It was the first selective,
irreversible inhibitor of gastric and pancreatic lipase enzymes.
Its mechanism of action involves the reduction of dietary fat
lipolysis and absorption (Al-Suwailem et al., 2006). It is a
prescription-only medicine in the European Union. Based on
the results of a meta-analysis, orlistat decreased average body
weight with 2.35 and 2.94 kg, at doses 60 and 120 mg, respectively
(Li et al., 2005). Its use may be associated with clinically relevant
mild-to-moderate gastrointestinal adverse effects (e.g. abdominal
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pain, diarrhea, fecal spotting, and steatorrhea). Apart from the
above-mentioned minor side-effects, serious adverse reactions
were also associated with the use of orlistat (e.g. subacute liver
failure, cholelithiasis and cholestatic hepatitis). The safety of the
chronic use of orlistat is highly questionable because it affects the
absorption of other pharmacons and fat-soluble vitamins
(Filippatos et al., 2008).
Liraglutide
Liraglutide acts as a glucagon like peptide-1 (GLP-1) receptor
agonist and it was first used for the treatment of T2DM (Collins
and Costello, 2019). Liraglutide was a promising pharmacon in
the therapy of T2DM, because it improved the patients’
cardiovascular status and outcome (Marso et al., 2016). After
being proved in human studies that GLP-1 analogues promote
weight loss, it has become an approved drug for weight
management. The mechanism of action of liraglutide involves
appetite suppression and delayed gastric emptying (Mehta et al.,
2017). Nevertheless, liraglutide was authorized by the European
Medicine Agency (EMA) as an adjunct to a comprehensive
lifestyle measures to induce weight loss (Supplementary Table
S1; Christou et al., 2016; EMA, 2020b).
Liraglutide is available as an injection, but another GLP-1
receptor antagonist, semaglutide can be given per os. Semaglutide
gained its EMA approval recently for the treatment of adults with
insufficiently controlled T2DM to improve glycemic control
(Gomez-Peralta and Abreu, 2019). Semaglutide is also
monitored; therefore, rapid identification of safety concerns
and unknown side effects are made possible (EMA, 2020a).
In human studies, the most common side effects associated
with the intake of liraglutide included gastrointestinal symptoms
(e.g. nausea and vomiting, risk of pancreatitis), and increased
pulse rate (Marso et al., 2016). In a clinical trial, from
randomization to the 20th week, the mean weight loss in the
intention-to-treat (ITT) population, was statistically significantly
bigger in the liraglutide treated groups when compared to
placebo. The effect was dose-dependent, daily doses of 1.2, 1.8,
2.8, and 3.0 mg liraglutide resulted in a weigh loss of 4.8, 5.5, 6.3,
and 7.2 kg, respectively. Taking placebo resulted in a 2.8 kg
weigh loss (Astrup et al., 2009).
Naltrexone-Bupropion
After subsequent clinical trials demonstrated its safety, a
combination therapy, containing naltrexone (2) and bupropion
(3) has been approved in the EU for weight management
(Supplementary Table S1). Naltrexone acts as an opioid
antagonist on the μ-opioid receptor and decreases appetite by
inhibiting β-endorphin-mediated autoinhibition of POMC (pro-
opiomelanocortin) neurons (Grossman et al., 2003; Cone, 2005;
Greenway et al., 2009). The anorectic effects of the antidepressant
bupropion is mediated via the stimulation of the activity of POMC
cells in the arcuate nucleus of the hypothalamus (Caixàs et al., 2014).
Significant weight loss was observed in participants assigned to the
combination group after the end of a 56-week-long trial. Patients in
the verum group received 32mg of naltrexone and 360mg
bupropion daily. In groups showing the highest weight loss, the
combination was applied for 28–36 weeks, mean change in
bodyweight was −6.1 kg (Greenway et al., 2009). Based on the
abovementioned evidence, this combinationmay serve as a possible
treatment adjunct to lifestyle modifications by promoting satiety,
reducing appetite, enhancing energy expenditure; therefore, it helps
patients to achieve weight loss goals (European Medicines Agency,
2015; Sherman et al., 2016). Initially, the first clinical trials focused
on the cardiovascular side effects of the combination (Sherman
et al., 2016; Tek, 2016). The combination of naltrexone and
bupropion is contraindicated in patients with uncontrolled
hypertension; however, the possible risks of this combination on
cardiometabolic parameters of the patients is not fully understood
(Connolly et al., 1997; James et al., 2010). Based on the clinical trials,
frequently occurring adverse effects in participants in the verum
groupwere nausea, headache, constipation, dizziness, vomiting, and
xerostomia (Vorsanger et al., 2016). Bupropion alone, and in
combination with naltrexone increases the blood pressure;
therefore, therapies in which bupropion is administered should
only be initiated in patients whose blood pressure is well-controlled.
Moreover, the patient’s blood pressure is to be checked regularly by
either the patient itself or by a health care professional throughout
the whole course of the treatment.
Phentermine
Phentermine (4) has great potential as a weight loss drug. It also acts
on the POMC neurons of the hypothalamus by inhibiting the
norepinephrine transporter (Narayanaswami and Dwoskin, 2017).
Weigh loss of up to 6 kg have been reported by taking phentermine
(15–30mg/daily) (Lonneman et al., 2013). Phentermine had been
used as an approved drug to overcome obesity in Europe since 1956
(Supplementary Table S1), and it was a frequently prescribed
medicine for decades (Colman, 2005). However, in 2012 the EMA
withdraw themarketing authorization of phentermine because of its
side-effects. Based on the published evidence, the compound might
affect the cardiovascular and the central nervous system when used
for a long time. Moreover, the authority was concerned about the
possibility of the use of the drug by obese adults for whom taking
phentermine may have deteriorating effects (Shin and Gadde,
2013). Nevertheless, phentermine resinate is available in
modified-release capsules in the Czech Republic based on the
authorization of the national competent authority (The State
Institute for Drug Control (SUKL), 2020). Phentermine was
combined with topiramate (PHEN/TPM) to achieve weight loss
goals and enhance quality of life of obese people. The combination
was to be used once daily, but its approval was withdrawn in Europe
in 2012, due to concerns regarding its safety (Shin and Gadde,
2013). Although, a 56-week-long trial conducted with a controlled
release formulation of phentermine and topiramate (containing
15 mg phentermine and 92mg topiramate) was proved to have an
outstanding efficacy; however, it has to be noted that its use
increased dose-dependently the occurrence of psychiatric and
cognitive adverse events (Scheen and Van Gaal, 2014).
Withdrawn Amphetamine Derivative-type
Medications in the European Union
Amphetamine and its derivates (e.g. phenylpropanolamine,
fenfluramine, dexfenfluramine) were used for obesity the first
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time in the 1930s (Bray and Greenway, 1999). These compounds
are mainly derived from phenylethylamine from which
neurotransmitters dopamine, epinephrine and norepinephrine
are derived. The weight loss mechanism of action of
amphetamine derivatives involves the stimulation of
norepinephrine- and dopamine-release in the hypothalamic
and limbic regions’ satiety centers (Bray, 1993). Amphetamine
derivatives exert their anorexigenic effect for a few hours; but
tolerance develops relatively fast within only a few weeks.
Amphetamine use and abuse often result in cardiac
complications (Bazmi et al., 2017). Amphetamine derivatives
used as weight loss therapy were removed from the legal
market in Europe due to safety concerns and the quick
development of tolerance (Supplementary Table S2).
Phenylpropanolamine
Phenylpropanolamine (PPA, 5) is available without prescription,
and commonly administered as an appetite suppressant for
weight loss, and also in cases of cough and common cold
(Kernan et al., 2000). PPA is chemically related to the
amphetamine-like anorectic agents (Walker et al., 1996).
Effects of PPA in weight loss is documented, but the exact
mechanism of action is not fully elaborated (Wellman and
Sellers, 1986).
Despite the fact that its safety and efficacy profile is
controversial, the drug is still available in some European
countries. There are safety concerns suggesting a link between
the consumption of PPA and stroke (Kernan et al., 2000). In a
clinical trial, complementary to a 5,023 kJ (1,200 kcal) diet,
patients in the verum group took 75 mg of sustained release
PPA for 6 weeks and the achieved weight loss was higher than in
the non-treated placebo group (Schteingart, 1992). Patients in the
verum group lost 2.59 kg, while the results in the placebo-
receiving group was less pronounced (−1.07 kg). 36 patients of
the original study were agreed to be enrolled in a further double-
blind trial up to 20 weeks, and the difference remained significant
(PPA −5.1; placebo −0.4 kg, p  0.01). In spite of the more weight
loss in the PPA group, patients did not report a greater
anorexigenic effect. The authors of the article concluded that
phenylpropanolamine can be used in combination with a diet
based on calorie deficit to promote safe weight management.
Fenfluramine, Dexfenfluramine
(+)-Norfenfluramine (6), the active metabolite of prodrugs
fenfluramine and dexfenfluramine, induces weight loss and it
is a potent agonist on 5-hydroxytryptamine (5-HT2C) receptors
(Porter et al., 1999; Fitzgerald et al., 2000). Both drugs,
fenfluramine and its (S)-isomer, dexfenfluramine were used in
monotherapy, the former one for short-term, and the latter one
for long-term weight management, even if its long-term safety
was not yet documented (Weintraub et al., 1992). The effects of
dexfenfluramine were examined on obese women (n  52) in a
placebo-controlled, double-blind study. Patients in the
dexfenfluramine group followed a 1,500 kcal/day diet and took
15 mg dexfenfluramine twice a day (Ditschuneit et al., 1996).
After completing the 12-months-long trial, patients in the verum
group lost 14.2 ± 2.20 kg, while patients in the placebo group lost
only 4.92 ± 2.99 kg. The side-effects of dexfenfluramine are quite
alarming though; based on a case-control study, it increased the
prevalence of cardiovascular diseases, and its use was associated
with pulmonary hypertension (Abenhaim et al., 1996). Therefore,
because of safety concerns, both drugs, and the so called fen-phen
formulation (combination of fenfluramine and phentermine)
were withdrawn from the market in 1997 (Weintraub et al.,
1992; Wadden et al., 1998; European Medicines Agency, 2003).
Withdrawn Non-amphetamine Derivative
Type Medications in the European Union
2,4-Dinitrophenol
The compound 2,4-dinitrophenol (DNP, 7) was initially applied in
explosive mixtures, but in 1933 it was discovered that DNP causes
significant weight loss, and soon it was marketed in slimming
products (Tainter et al., 1933). DNP contributes to weigh
management by increasing the basal metabolic rate (Cutting
et al., 1933). However, serious adverse effects occurred so often
that it was withdrawn from the market, and it was labelled as an
‘extremely dangerous’ drug (Supplementary Table S3; Tainter
et al., 1934; McFee et al., 2004; Colman, 2007). The side-effects of
DNP are associated with its mechanism of action: DNP induces a
hyper-metabolic state of the body via uncoupling oxidative
phosphorylation, and the excess energy becomes thermal energy
in the mitochondria. Hyper-metabolite state is followed therefore
with an uncontrolled thermogenesis causing hyperthermia and
undesirable elevated body temperature associated with systemic
responses (Tainter et al., 1935). After 1938, DNP was no longer
prescribed and reports on severe side-effects did not occur, but it is
assumed that the use of the compound has not been vanished
completely, because case reports of DNP caused deaths still
emerged after it has been withdrawn from the legal market
(Colman, 2007). Today, DNP is sold illegally as a weight loss
aid under a number of different names and its use is encouraged by
reports of rapid and safe weight loss (McFee et al., 2004).
Rimonabant
Rimonabant (8), the first antagonist on the cannabinoid receptor
type 1 (CB1-receptor) entered the European market in 2006
(Supplementary Table S3) (Rinaldi-Carmona et al., 1995).
Initially, it was a promising medication, since several trials
proved its effects on weight loss and it also improved several
parameters of metabolic syndrome. A meta-analysis of RCTs
evaluating the efficacy and safety of rimonabant (20 mg/day)
found that the average weight loss in the treated group was 4.7 kg
(4.1–5.3 kg), significantly higher, compared to the placebo group
(Christensen et al., 2007). However, the use of rimonabant was
linked to diverse psychiatric adverse events (e.g. anxiety,
depression, and suicidal ideation); therefore, the EMA
withdrew the market authorization of rimonabant in the EU
in January 2009 (Sam et al., 2011).
Sibutramine
The antidepressant sibutramine (9) inhibits the reuptake of
neurotransmitters serotonin (5HT)- and noradrenaline (NA).
Apart from its original application later on it was found to
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reduce appetite (McNeely and Goa, 1998). In a 12-week-long
study, the effects of sibutramine was similar to that of
dexfenfluramine. Patients in both groups lost significant
amount of weight (4.5 kg, and 3.2 kg, respectively).
Sibutramine was used at daily doses ranging from 5 to 30 mg.
Based on the results of this study, the optimum daily dose of the
drug is 10–15 mg (Lean, 1997). After reports on increased
diastolic and systolic blood pressure and pulse rate, concerns
were raised regarding the safety of sibutramine (Sharma et al.,
2009). Hence, its safety was assessed in the so called Sibutramine
Cardiovascular Outcomes Trial (SCOUT) (James, 2005). In this
trial the harmlessness of sibutramine was evaluated on patients
with a history of cardiovascular disease. As a result, the EMA
concluded that the risk-benefit ratio was unfavorable for
sibutramine and recommended to suspend all marketing
authorizations for sibutramine-containing medicines in Europe
(Williams, 2010). Sibutramine was approved in 2001, whereas its
market authorization was suspended in 2010 (Supplementary
Table S3; Ioannides-Demos et al., 2005).
Lorcaserin
Lorcaserin (10), an 5-HT2C receptor agonist, was an approved
drug for long-term treatment of obesity and it was intended to be
used along with reduced-calorie diet and increased physical
activity (Smith et al., 2010). In 2013 (Supplementary Table
S3), only one year after its marketing approval, the marketing
authorization holder officially notified the EMA’s Committee for
Medicinal Products for Human Use (CHMP) about his wish to
withdraw the marketing authorization for lorcaserin, because
based on the CHMP’ opinion the benefits of lorcaserin—a
medicine intended for helping to achieve weight control in
obese and overweight patients—did not outweigh its risks (e.g.
depression, valvulopathy) (European Medicines Agency, 2013).
The weight loss achieved after a one year treatment with
lorcaserin ranged from 4.5 to 5.8 kg in the published clinical
trials when taking 10 mg lorcaserin once or twice daily (Fidler
et al., 2011). Patients taking lorcaserin experienced a significant
increased risk of depression (DiNicolantonio et al., 2014). Long-
term use might be associated with increased cancer risk
(LiverTox, 2012b).
FOOD SUPPLEMENTS FOR WEIGHT LOSS
Considering the limited efficacy and unfavorable side-effect
profiles of synthetic drugs, there is a high demand for
alternative treatments like herbal products to induce weight
loss (Bahmani et al., 2015). One further reason for turning to
alternative preparations is the fear from the possible side-effects
of synthetic drugs. However, natural origin does not guarantee
safety, as it can be demonstrated on the example of ephedrine, a
natural alkaloid of species of Ephedraceae having a remarkably
high cardiovascular risk (Samenuk et al., 2002). It is a myth that
the use of herbal substances are always safe and harmless, and it is
important to highlight that herbal compounds can have an
interaction with medicines and products of natural origin can
cause adverse events as well (Pittler and Ernst, 2001; Dwyer et al.,
2005; Poddar et al., 2011; Astell et al., 2013). Moreover, since the
regulation and control of food supplements is less strict compared
to medicines, the ratio of conterfeit or mislabbelled, potentially
dangerous products might be higher.
According to a recent review, most popular natural ingredients
marketed for weight management include chitosan,
glucomannan, capsaicin, carnitine, and conjugated linoleic acid
(CLA) (Wharton et al., 2020). In Europe, other popular herbal
ingredients include Camellia sinensis (L.) Kuntze (Theaceae),
Garcinia cambogia (Gaertn.) Desr. (Clusiaceae) and unroasted
seed of Coffea arabica L. (Rubiaceae) (Barrea et al., 2019; Ríos-
Hoyo and Gutiérrez-Salmeán, 2016; The Plant List, 2013).
Hoodia gordonii (Masson) Sweet ex Decne. (Apocynaceae),
Stevia rebaudiana (Bertoni) Bertoni (Compositae), Acaciopsis
rigidula (Benth.) Britton and Rose (Leguminosae family, syn.
of Acacia rigidula) also occurred frequently as constituent of
weight loss products in the warnings of RASFF (The Plant List,
2013). In the following, we present an overview of the most
popular ingredients of weight loss products, including some
plants that were common constituents of products reported in
the RASFF system.
Chitosan
Chitosan, a polysaccharide composed of β-(1→4)-linked
D-glucosamine and N-acetyl-D-glucosamine units, is formed by
the deacetylation of chitin. This compound can be found in the
animal kingdom (e.g. the exoskeleton of crustaceans and insects)
(Mesa Ospina et al., 2015). It contributes to weight management
by lowering the absorption of dietary fat and cholesterol, and it
might also promote fat excretion leading to weight loss without
dietary modifications (Pokhis et al., 2015). A meta-analysis of 14
RCTs studied the effects of chitosan on body weight, serum lipids
and blood pressure (Moraru et al., 2018). The results indicated
that by the use of chitosan as a food supplement for up to
52 weeks might promote weight loss (average −1.01 kg). Apart
form its slight effects on the body weight, the consumption of
chitosan was associated with improvements of serum lipid profile
and a significant reduction blood pressure, both systolic and
diastolic (−2.68 mmHg, and −2.14 mmHg, respectively).
Based on the published studies, the short-term use of chitosan
is safe, but except for those with shellfish allergy (Waibel et al.,
2011). Adverse effects include flatulence, constipation,
indigestion, nausea, and heartburn (Gallaher et al., 2000).
Chitosan might interact with warfarin and partially interferes
with the absorption of the fat-soluble vitamins (i.e. vitamins A, D,
E, and K); however, its effects on the fecal fat excretion are not
fully proven (Huang et al., 2007; Jull et al., 2008).
Glucomannan
The most commonly used type of glucomannan (GM) in weight
loss products is extracted from tubers of Amorphophallus konjac
K. Koch (Araceae) (Xiao et al., 2000, The Plant List, 2013). GM, a
hemicellulose-type polysaccharide induces weight loss through
several mechanism. It makes the absorption in the small intestine
slower; however, reduces the transit time in the small intestine,
because it increases the viscosity of the content; furthermore, GM
increases energy loss via fecal excretion. GM induces satiety in
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several ways: the consumption of GM enhances mastication
efforts, and after its consumption it delays gastric emptying;
moreover, elevated levels of plasma cholecystokinin induces
cephalic– and gastrointestinal-phase satiety signals (Gallaher
et al., 2000; Ríos-Hoyo and Gutiérrez-Salmeán, 2016). A meta-
analysis found that the daily consumption of GM (1.2–15.1 g/
day) for 5 weeks improves the patient’metabolic profile, but only
slightly affects the body weight (WMD: −0.79 kg) (Sood et al.,
2008). However, contrasting results were reported by Zalewski
and Szajewska, 2015, claiming that in otherwise healthy
overweight or obese adults, short-term use of GM may
promote a slight weight loss, but it does not affect the BMI.
The effects of GM on children are not enough to establish a firm
conclusion. Mild gastrointestinal adverse effects (bloating,
diarrhea) were associated with the use of GM (Keithley and
Swanson, 2005).
Capsaicin
Capsaicin (11) and capsaicinoids are agonists of the TRPV1
(transient receptor potential vanilloid subfamily 1) receptor,
and they mimic the effects of cold, which decreases the fat
mass through the activation and recruitment of brown adipose
tissue (Saito, 2015). Capsaicin affects the oxidation of lipid and
influences energy expenditure (Whiting al., 2014; Ludy et al.,
2012; Zheng et al., 2017). Food rich in capsaicin contributes to
weight management by preventing obesity (Zheng et al., 2017).
There are also reports that the body weight of healthy women
who regularly use chili peppers is slightly reduced when
compared to those who do not use chili (Henry and Emery,
1986; Yoshioka et al., 1998). A meta-analysis based on eight
studies involving 191 participants concluded that patients who
took 2 mg capsaicin before each meal consumed less calorie by an
average of 74 kcal; therefore, capsaicin may help maintain weight
by reducing total energy intake (Whiting et al., 2014). However,
based on other literature data, the level of its effects on
thermogenesis and fat oxidation is moderate and its long-term
efficacy is questionable (Lejeune et al., 2003). A middle-aged man
with normal BMI would lose approximately 0.5 kg over 6.5 years
if he pursued a calorie deficit diet of 10 kcal and consumed
hedonically acceptable doses of capsaicin (Ludy et al., 2012),
whereas a weight loss of 2.6 kg over 8.5 years would be reachable if
he was in a 50 kcal negative energy balance (Galgani and
Ravussin, 2010; Hall, 2010). Capsaicin at acceptable doses is
safe, although it might cause mild-to-moderate gastrointestinal
side-effects, sweating, flushing, and rhinorrhea (Avesaat et al.,
2016). In addition, capsaicin compounds can interfere with
antihypertensive agents (Patanè et al., 2010).
Carnitine
Carnitine (12) transports long-chain fatty acids (FAs) into the
mitochondria for transformation, and energy is produced from
these FAs via β-oxidation, and it also aids eliminate toxic
compounds from the cell (NIH, 2017). L-carnitine is the
isomer of carnitine that is used to enhance weight loss
(Elmslie et al., 2006). Nine RCTs involving 911 patients were
summed up and analyzed in a systematic review and meta-
analysis (Pooyandjoo et al., 2016). Participants receiving
carnitine (in doses varying from 1.8 g/day to 4 g/day) lost
significantly more weight (−1.33 kg) and their BMI decreased
significantly more (−0.47 kg/m2) than patients receiving the
control treatment. The results revealed that the weight loss
effects of carnitine diminished over time. L-carnitine is very
well tolerated; at doses of up to 15 g daily and there were only
a few, mild side effects like infrequent diarrhea, gastralgia and
nausea (Goa and Brogden, 1987).
Conjugated Linoleic Acid
Conjugated linoleic acid (CLA) and its isomers activate different
nuclear receptors and, thus, they differentially regulate the
expression of those genes that are related to lipid metabolism
(Chin et al., 1994). The natural sources of are beef meat and dairy
products, but it can also be found in dietary supplements (Schmid
et al., 2006). A meta-analysis of human studies indicated that the
effect of CLA on weight loss was superior to that of the placebo:
median doses of 3.2 g was effective and reduced fat mass
(Whigham et al., 2007). However, in certain studies, the
association between CLA and weight loss was not observed
(Wharton et al., 2020). Nevertheless, there is a clear need for
further, larger human trials assessing the efficacy and safety of
CLA dietary supplements (Whigham et al., 2004). In animal
studies CLA interfered with glucose metabolism (e.g. increased
insulin resistance in mice) and lead to a change in liver function
inducing lipodystrophy; therefore, these effects should be
evaluated in human studies as well to rule out any safety
concerns (Clément et al., 2002).
Green Coffee
Unroasted seed of Coffea arabica L. are good sources of
chlorogenic acids (13) that are not present in roasted coffee
because of their thermolability (Farah et al., 2008). The
possible use of green coffee in weight management is related
to its chlorogenic acid content (Shimoda et al., 2006).
Chlorogenic acid-rich green coffee extracts reduce blood lipid
and glucose levels, blood pressure, and reduce the risk of certain
cardiovascular diseases (Sanlier et al., 2019). A meta-analysis of
three RCTs involving a total of 142 participants revealed that by
the consumption of green coffee extract (GCE) a significant
reduction in body weight was achieved (Onakpoya et al.,
2011b). The authors of the above-mentioned meta-analysis
could not establish an effective dose for the extract. The grade
of evidence of this analysis is moderate, and if more rigorous trials
with longer duration are published, the efficacy and safety of GCE
in weight management might become appraisable.
Green Tea
The non-fermented leaves of Camellia sinensis (L.) Kuntze is green
tea. Its main active compounds are catechin polyphenols, such as
epicatechin, epigallocatechin, epicatechin-3-gallate and
epigallocatechin-3-gallate (EGCG, 14). From these constituents,
EGCG is the one in which green tea is the most abundant and this
compound is the most important with respect to its
pharmacological effects (Musial et al., 2020). Caffeine is also a
major pharmacologically active ingredient of green tea
(Jeukendrup and Randell, 2011). It was found that a
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combination of green tea and caffeine contributed to weight
management in people who usually consume low amounts of
caffeine. The effect was attributed to enhanced thermogenesis
and fat oxidation (Dulloo et al., 1999). This might be explained
by the caffeine content of tea, since high doses of caffeine elevates
thermogenesis and fat oxidation and lowers leptin levels; therefore,
it might have body weight reducing effects (Westerterp-plantenga
et al., 2005). Moreover, catechins, especially EGCG, inhibits
catechol-O-methyltransferase (COMT) and therefore enhances
fat oxidation (Westerterp-plantenga et al., 2005). A meta-
analysis of human studies carried out with green tea proved
that EGCG-containing extracts have significant effect on weight
loss and its maintenance (WMD: −1.31 kg; duration at least 12
weeks). When analyzing the data from studies in which high
regular caffeine intake was recorded, the effect of caffeine intake
on body weight was not significant. However, the studied
population differed in these two groups, i.e. low caffeine intake
was studied on Asian participants and moderate-to-high caffeine
doses were studied in Caucasian people; therefore, the conflicting
results might derive form the heterogeneity of the included studies
(Hursel et al., 2009). Green tea extracts are common constituents of
slimming products; however, there are concerns about the
hepatotoxicity of extracts with high (>100 mg/day) EGCG
content (Oketch-Rabah et al., 2020).
Garcinia cambogia
The main acid compound of Garcinia cambogia (Gaertn.) Desr. is
(-)-Hydroxycitric acid (HCA, 15). This compound have proven
adenosine triphosphate (ATP) citrate lyase inhibitory effects
(Watson et al., 1969). The inhibition of the above mentioned
enzyme restricts the availability of acetyl coenzyme A (acetyl-CoA)
units that are necessary for fatty acid synthesis and lipogenesis
during a so called lipogenic diet when patients consume high
amounts of carbohydrates (Kornacker and Lowenstein, 1965;
Bressler and Brendel, 1966; Linn and Srere, 1979). The
compound restrains the synthesis of FAs, lipogenesis, appetite,
and therefore aids weight loss (Sullivan et al., 1972). Despite its
promising mechanisms, clinical studies have shown controversial
findings (Jena et al., 2002). Nine RCTs were analyzed in a meta-
analysis which revealed a small but significant weight loss
promoting effect of HCA when compared to placebo
(Onakpoya et al., 2011a). The duration of the included studies
varied from 2 to 12 weeks, and the participants took 1–2.8 g of
HCA daily. More recently, cases of acute liver injury have been
emerged in association with a product claimed to contain Garcinia
cambogia. It is alarming that not only mild side effects (transient
and moderate enzyme elevations) were reported but symptomatic
acute hepatitis and acute liver failure were also described
(LiverTox, 2012a). The frequency of hepatic adverse reactions is
not known but it seems to be uncommon (<1:10,000). HCAmight
influence glucose homeostasis bymodifying insulin sensitivity, and
increasing gluconeogenesis and the formation of ketone bodies
(McCarty and Majeed, 1994; Jena et al., 2002).
Hoodia gordonii
The consumption of Hoodia gordonii (Masson) Sweet ex Decne.
has its tradition among a native South African people (van
Heerden, 2008). Bushmen used to eat this succulent plant for
its appetite reducing effects. In Europe, H. gordonii can only be
marketed after appropriate safety assessment, since it was not
used as a food or food ingredient before 15 May 1997 (European
Commission, 2020). An oxypregnane glycoside, P57 (16) is
assumed to be responsible for the appetite reducing effects of
H. gordonii. It was found that after intracerebroventricular
administration, P57 increased ATP production in the
hypothalamus (MacLean and Luo, 2004). No published, peer-
reviewed meta-analysis of RCTs examining the efficacy ofHoodia
were found in the literature (PubMed/Medline, the Cochrane
Library, ClinicalKey and Google Scholar). In a placebo-controlled
study involving overweight women, the weight loss efficacy of H.
gordonii was compared to placebo. Participants were classified by
body fat percentages, and 25 of them took H. gordonii and 24
received placebo (Blom et al., 2011). To ensure identical
circumstances for each participant during the 15-day-long
study, they stayed in the clinic 4 days prior to the study for a
run-in period and during the 15-days treatment period.
Participants were asked to consume a yogurt drink 1 h prior
to each breakfast and dinner. The yogurt contained 1,110 mg H.
gordonii or placebo. There were no serious adverse events but
nausea, vomiting, and disturbances of skin sensation occurred in
the verum group. Blood pressure, pulse rate, bilirubin and
alkaline phosphatase levels increased significantly in the verum
group. Recently alarming side effects (elevated blood pressure and
heart rate) that are in line with the previously describe study have
been reported (Roza et al., 2013).
Stevia rebaudiana
The plant Stevia rebaudiana (Bertoni) Bertoni is native to South
America, and Native Americans used it for centuries to sweeten
their food and also for medicinal purposes, as herbal tea to
alleviate several ailments, such as heartburn (Lemus-Mondaca
et al., 2012). Glucosides obtained from S. rebaudiana are
approximately 300 times sweeter than sucrose. Nowadays,
when obesity has become a worldwide problem, low- and no-
calorie sweeteners, such as S. rebaudiana offers an alternative that
might help reduce sugar intake, and decrease the incidence of
diseases derived from high refined sugar consumption (Samuel
et al., 2018).
The whole plant and also the dried leaves of S. rebaudiana are
novel foods in the EU based on the Regulation (EC) No 258/97
(European Commission, 1997). Extracts prepared from the leaves
of S. rebaudiana are authorized as novel food, based on the
Regulation (EC) No 1333/2008 on food additives or Regulation
(EC) No 1334/2008 on flavorings, respectively (European
Commission, 2008). The regulation covers only herbal tea
containing or prepared with leaves of S. rebaudiana and
preparations that are to be used for sweetening or flavoring
purposes, every other use of Stevia is still unauthorized in the
European Union.
S. rebaudiana appears to be safe. Human and animal studies
have shown that steviol glycosides do not possess nor
carcinogenic, nor mutagenic, nor teratogenic activates, and
they do not have acute or subacute toxicity (Momtazi-Borojeni
et al., 2017).
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Acacia rigidula
Extracts of Acaciopsis rigidula (Benth.) Britton and Rose leaves
are used in weight loss products with little or no published clinical
data about their potential biological effects, and has no
documented history of use as food or traditional herbal
treatment (Pawar et al., 2014). A comprehensive literature
search in several databases (PubMed/Medline, the Cochrane
Library, ClinicalKey and Google Scholar) yielded no results
regarding its safety and efficacy. The consumption of A.
rigidula might be dangerous because it contains appreciable
amounts of toxic azotoids (Clement et al., 1998). A. rigidula is
still not a novel food in the European Union, hence it cannot be
market as food supplement, only taxons Acacia arabica (Lam.)
Willd., Acacia nilotica(L.) Delile, Acacia senegal (L.) Willd. and
Acacia verek Guill. and Perr. are authorized as a novel food
ingredient (European Commission, 2020).
MATERIALS AND METHODS
Retrospective data were extracted from the RASFF portal. Data
from individual warnings were recorded (date, product, product
category, notification type, countries concerned, subject, action
taken, distribution status and risk decision). Records were
grouped into four main categories:
(1) “A” for unauthorized ingredients;
(2) “B” for unsafe ingredients;
(3) “C” if there was a problem with the level of the ingredient
(too high or too low);
(4) “D” other problems (eg mislabeling, taste disturbance).
RASFF signals are classified as alert, information notification
or border rejection as part of its RASFF Portal. Subcategories were
created based on the intended use of the reported product. The
risks and adverse effects were also assessed. Data from 1988 to
2019 were extracted from the reported supplements database on
January 1, 2020. Each entry was individually reviewed. After the
data set was categorized, descriptive analyses were performed
usingMicrosoft Excel 2010 (Microsoft Excel, RRID:SCR_016137)
for Windows (Microsoft Inc.).
RESULTS
The raw data set from the RASFF database included 2,559 records
of food supplements with quality problems and several of these
products were marketed to facilitate weight loss [319 (12.5%)].
202 (63.3%) of these slimming products contained unapproved,
synthetic weight loss pharmacons. Other frequently used
adulterants were erectile dysfunction drugs and performance-
enhancers which are not included in this article.
The overall reports extracted from RASFF show that the first
notifications were created in 2003, and the number of the
reported signals kept growing until 2019 (especially in case of
DNP). The majority of the adulterated anti-obesity products
contained DNP (113 of 319, 35.4%). Sibutramine was the
second most frequent adulterant (69 products, 21.6%) in the
weight loss food supplement category and it was reported in
almost every year, in contrast with DNP, which was reported only
in four different years, in 2003, 2017, 2018, 2019.
Phenolphthalein, a laxative with genotoxic and carcinogenic
potential was the less common synthetic adulterant, with 20
reports. Unauthorized plant ingredients such as Hoodia
gordonii (Masson) Sweet ex Decne., Stevia rebaudiana
(Bertoni) Bertoni, and Acaciopsis rigidula (Benth.) Britton and
Rose (in RASFF portal recorded as syn.: Acacia rigidula) were
reported less frequently (Figure 1).
Based on our statistical overview, adulterated DNP products
have been reported mainly in the United Kingdom. Whereas
sibutramine has been reported with the highest number in
Germany followed by Cyprus and Slovenia, it was reported
less frequently in other countries (Supplementary Figure S1).
Based on the reports, DNP as adulterant first appeared in
2003, in Finland, and there were no reports on DNP until 2017,
and then in 2017, it appeared again, and the number of DNP-
containing products started to increase dramatically. The
notifications originated from the United Kingdom and Cyprus.
Sibutramine was first detected in food supplements in the
2005, and since then it is a common adulterant in the EU. The
number of reports on sibutramine-containing products peaked in
2012 (21 reports) and concerned many countries in the EU. The
first 2 phenolphthalein reports originated from Hungary and
Cyprus. The maximum number of phenolphthalein was seven
reports in 2013 from Germany (Supplementary Table S4).
The ratio of the emergence of these three, commonly used
synthetic compounds can be seen in Supplementary Figure S2.
Based on the reports, it can be concluded that sibutramine
emerged more frequently, but it occurred in fewer products.
DNP was mainly present in 2018 (41 times) and in 2019 (70
times), while the popularity of sibutramine seemingly peaked in
the early 2010s, in 2011 and 2012 14 and 21 reports were
registered, respectively. Phenolphthalein emerged with the
highest reports in 2012 with six reports and with seven reports
in 2013.
Based on the RASFF signals Hoodia gordonii [66 of 117
(56.4%)], Stevia rebaudiana [23 (19.66%)] and Acacia rigidula
[28 (23.93%)] were reported as unauthorized herbal products.
The countries affected by adulterated products were Poland,
Lithuania, France, Malta, Spain, Belgium, Austria, Switzerland,
Ireland, Sweden, and Finland as shown in Supplementary
Figure S3.
Hoodia gordonii was reported for the first time, in 2005 in the
Netherlands (2 reports). The greatest number of products containing
Hoodia goordonii was reported in 2017 (30 reports). In 2016, there
were no reports on Hoodia gordonii. The first appearance of a
product containing unauthorized Stevia rebaudiana was reported in
Denmark in 2006. The highest number of reports on products
containing unathorized Stevia rebaudiana was four in 2010. Except
for 2005, 2015, 2018, 2019, it was present in every year from
1988–2019. Acacia rigidula was first reported in 2016, firstly in
the Netherlands, but later also in Belgium, Austria, France, Malta,
Spain and other European countries, overall 28 records were found
in RASFF (Supplementary Table S5).
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The ratio of these three reported, natural products with safety
concerns are represented in Supplementary Figure S4. Hoodia
gordonii was present more often, in smaller quantities, with the
highest occurrence of 30 reports in 2017. Stevia rebaudiana has
been reported in almost every year, but the highest number of
reports was only four. The appearance of Acacia rigidula only
started at 2016 and it emerged again in 2017 with 23 records.
DISCUSSION
The aim of our work was to summarize the trends concerning
adulterated food supplements associated with a warning released
by the RASFF between 1988 and 2019, focusing on products with
intended use as slimming agent. RASFF is a platform for
reporting food safety issues within the European Union. When
a RASFF member suspects that a food or feed poses a serious risk
to the people’s health, the member state should notify the
European Commission (EC) via RASFF without any delay. In
cases of withdrawing or recalling products from their market or in
cases when rapid measures are needed, the members are obliged
to notify the EC to help protect peoples’ health.
The increasing number of signals on illegal food supplements
in RASFF reveals that the presence of undeclared ingredients
poses an important public health concern. Illegal supplements
marketed for weight loss were most commonly adulterated with
DNP or sibutramine between 1988 and 2019. The use of former
one may result in quick weight loss, but often causes serious
adverse events (Colman, 2007). Several deaths attributable to
DNP have been published (Cann and Verhulst, 1960). DNP was
detected as an adulterant for the first time in 2003, but the
number of products containing this compound has been
increasing from 2017 through 2019, reported mainly in the
United Kingdom. Sibutramine was reported in several
countries; however, the number of products containing
sibutramine was lower. SCOUT confirmed that sibutramine
(at daily doses ranging from 10 to 15 mg) increases the risk
for nonfatal myocardial infarction and nonfatal stroke in patients
with preexisting cardiovascular disease, and have an increased
potential to develop high blood pressure or pulse rate (Sharma
et al., 2009).
It is alarming that the majority of the reported signals were in
connection with unsafe synthetic substances. There have been
increasing number of reports on DNP, and since this substance
can cause serious side effects it is necessary to monitor the use of
DNP more closely in the future.
Out of the most popular food supplements with natural origin
the extracted materials of Hoodia gordonii (Masson) Sweet ex
Decne., Stevia rebaudiana (Bertoni) Bertoni, and Acaciopsis
rigidula (Benth.) Britton and Rose were unauthorized products
registered in RASFF from 1988–2019. Stevia rebaudiana seems to
be the least dangerous component based on the reports of our
review on RASFF. It was reported in small quantity, and for now
became authorized as a novel food according to EC Regulation
EC No. 258/97 (European Commission, 1997). In spite of that it
has been traditionally used for hundreds of years, more scientific
and clinical studies are needed to verify its safety, because it was
represented almost in every year in RASFF from 1988–2019, and
it is very popular among the consumers.
The other two plants (H. gordonii, A. rigidula) are still not
authorized as a novel food and their safety is not scientifically
proven (Roza et al., 2013; Clement et al., 1998).
Despite the fact thatH. gordonii is often used as an adulterant,
and advertised for its weight loss promoting effects, there is still
little known about its chemical constituents and their mechanism
of action. Recent research suggests that the use H. gordonii may
cause increased blood pressure and pulse rate (Roza et al., 2013).
Taken into consideration thatH. gordonii emerges regularly from
1988, it would be important to monitor food supplements
containing Hoodia.
FIGURE 1 | Notifications on weight loss food supplements in the RASFF (2003–2019).
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A. rigidula is a shrub native to the Southeastern United States,
and it contains several biogenic amines. The plant has been
marked in products promoting weigh loss; however, its effects
are not yet supported by either its traditional usage, since it has
never been used in the traditional medicine, or by research results.
Acacia rigidula occurred in the RASFF portal recently, the
presence of A. rigidula should be monitored closely in weight
loss dietary supplements.
CONCLUSION
As several medications used to manage body weight are no longer
available on the market, because of their serious adverse effects;
there is a clear need for effective products to support weight loss
because currently there are only a few therapeutic options to
address this issue. However, the efficacy of natural ingredients
usually does not meet the customers’ expectations.
Some products (typically sold as food supplements) are
adulterated with synthetic compounds to increase their
efficacy. Adulterated food supplements may cause serious
adverse effects, and their interactions with other medicines are
also unpredictable. Therefore, it is alarming that the number of
signals on adulterated products in RASFF is increasing. As the
food supplement industry continues to grow worldwide, it is
important to mark these signals as a public health issue, and to
elaborate various measures to decrease the number of these
signals by improving the safety, quality and testing of food
supplements.
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